OBJECTIVES: The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/orhepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials. METHODS: Patients received 25 mg of rilpivirine once daily or 600 mg of efavirenz once daily, plus two nucleoside/nucleotide reverse transcriptase inhibitors. At screening, patients had alanine aminotransferase/aspartate aminotransferase levels ≤5× the upper limit of normal. HBV and HCV status was determined at baseline by HBV surface antigen, HCV antibody and HCV RNA testing. RESULTS:HBV/HCV coinfection status was known for 670 patients in therilpivirine group and 665 in the efavirenz group. At baseline, 49 rilpivirine and 63 efavirenz patients [112/1335 (8.4%)] were coinfected with either HBV [55/1357 (4.1%)] or HCV [57/1333 (4.3%)]. The safety analysis included all available data, including beyond week 48. Eight patients seroconverted during the study (rilpivirine: five; efavirenz: three). A higher proportion of patients achieved viral load <50 copies/mL (intent to treat, time to loss of virological response) in the subgroup without HBV/HCV coinfection (rilpivirine: 85.0%; efavirenz: 82.6%) than in the coinfected subgroup (rilpivirine: 73.5%; efavirenz: 79.4%) (rilpivirine, P = 0.04 and efavirenz, P = 0.49, Fisher's exact test). The incidence of hepatic adverse events (AEs) was low in both groups in the overall population (rilpivirine: 5.5% versus efavirenz: 6.6%) and was higher in HBV/HCV-coinfected patients than in those not coinfected (26.7% versus 4.1%, respectively). CONCLUSIONS: Hepatic AEs were more common and response rates lower in HBV/HCV-coinfected patients treated with rilpivirine or efavirenz than in those who were not coinfected.
RCT Entities:
OBJECTIVES: The efficacy and hepatic safety of the non-nucleoside reverse transcriptase inhibitors rilpivirine (TMC278) and efavirenz were compared in treatment-naive, HIV-infected adults with concurrent hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection in the pooled week 48 analysis of the Phase III, double-blind, randomized ECHO (NCT00540449) and THRIVE (NCT00543725) trials. METHODS:Patients received 25 mg of rilpivirine once daily or 600 mg of efavirenz once daily, plus two nucleoside/nucleotide reverse transcriptase inhibitors. At screening, patients had alanine aminotransferase/aspartate aminotransferase levels ≤5× the upper limit of normal. HBV and HCV status was determined at baseline by HBV surface antigen, HCV antibody and HCV RNA testing. RESULTS:HBV/HCV coinfection status was known for 670 patients in the rilpivirine group and 665 in the efavirenz group. At baseline, 49 rilpivirine and 63 efavirenzpatients [112/1335 (8.4%)] were coinfected with either HBV [55/1357 (4.1%)] or HCV [57/1333 (4.3%)]. The safety analysis included all available data, including beyond week 48. Eight patients seroconverted during the study (rilpivirine: five; efavirenz: three). A higher proportion of patients achieved viral load <50 copies/mL (intent to treat, time to loss of virological response) in the subgroup without HBV/HCV coinfection (rilpivirine: 85.0%; efavirenz: 82.6%) than in the coinfected subgroup (rilpivirine: 73.5%; efavirenz: 79.4%) (rilpivirine, P = 0.04 and efavirenz, P = 0.49, Fisher's exact test). The incidence of hepatic adverse events (AEs) was low in both groups in the overall population (rilpivirine: 5.5% versus efavirenz: 6.6%) and was higher in HBV/HCV-coinfectedpatients than in those not coinfected (26.7% versus 4.1%, respectively). CONCLUSIONS: Hepatic AEs were more common and response rates lower in HBV/HCV-coinfectedpatients treated with rilpivirine or efavirenz than in those who were not coinfected.
Authors: Calvin J Cohen; Jean-Michel Molina; Pedro Cahn; Bonaventura Clotet; Jan Fourie; Beatriz Grinsztejn; Hao Wu; Margaret A Johnson; Michael Saag; Khuanchai Supparatpinyo; Herta Crauwels; Eric Lefebvre; Laurence T Rimsky; Simon Vanveggel; Peter Williams; Katia Boven Journal: J Acquir Immune Defic Syndr Date: 2012-05-01 Impact factor: 3.731
Authors: Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: P J Peters; J Stringer; M S McConnell; J Kiarie; W Ratanasuwan; P Intalapaporn; D Potter; W Mutsotso; I Zulu; C B Borkowf; O Bolu; J T Brooks; P J Weidle Journal: HIV Med Date: 2010-11 Impact factor: 3.180
Authors: M Savès; F Raffi; P Clevenbergh; B Marchou; A Waldner-Combernoux; P Morlat; V Le Moing; C Rivière; G Chêne; C Leport Journal: Antimicrob Agents Chemother Date: 2000-12 Impact factor: 5.191
Authors: Melanie A Thompson; Judith A Aberg; Pedro Cahn; Julio S G Montaner; Giuliano Rizzardini; Amalio Telenti; José M Gatell; Huldrych F Günthard; Scott M Hammer; Martin S Hirsch; Donna M Jacobsen; Peter Reiss; Douglas D Richman; Paul A Volberding; Patrick Yeni; Robert T Schooley Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471
Authors: Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2013 Impact factor: 2.471
Authors: Viviane D Lima; Anja Reuter; P Richard Harrigan; Lillian Lourenço; William Chau; Mark Hull; Lauren Mackenzie; Silvia Guillemi; Robert S Hogg; Rolando Barrios; Julio S G Montaner Journal: AIDS Date: 2015-09-10 Impact factor: 4.177
Authors: Karin Neukam; Nuria Espinosa; Dolores Merino; Antonio Rivero-Juárez; Ana Carrero; María José Ríos; Josefa Ruiz-Morales; Ana Gómez-Berrocal; Francisco Téllez; Marta Díaz-Menéndez; Antonio Collado; Inés Pérez-Camacho; Marcial Delgado-Fernández; Francisco Vera-Méndez; Juan A Pineda Journal: J Int AIDS Soc Date: 2014-11-02 Impact factor: 5.396
Authors: Mark Hull; Stephen Shafran; Alex Wong; Alice Tseng; Pierre Giguère; Lisa Barrett; Shariq Haider; Brian Conway; Marina Klein; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2016-07-04 Impact factor: 2.471
Authors: Karin Neukam; Nuria Espinosa; Antonio Collado; Marcial Delgado-Fernández; Patricia Jiménez-Aguilar; Antonio Rivero-Juárez; Victor Hontañón-Antoñana; Ana Gómez-Berrocal; Josefa Ruiz-Morales; Dolores Merino; Ana Carrero; Francisco Téllez; María José Ríos; José Hernández-Quero; María de Lagarde-Sebastián; Inés Pérez-Camacho; Francisco Vera-Méndez; Juan Macías; Juan A Pineda Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240